Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

NCT00634712 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 734

Last updated 2011-01-25

No results posted yet for this study

Summary

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Candesartan

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Dr Salim Yusuf

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-06-30
Primary Completion
2003-05-31
Completion
2003-05-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00634712 on ClinicalTrials.gov